{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-007153","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.504729+00:00","generated_at":"2026-06-22T04:59:02.259672+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cassava Sciences Q3 net loss $20.3M; Phase 3 Alzheimer's trial enrollment tops 650","bullets":["Net loss $20.3M ($0.51/share) vs $9.6M loss in Q3 2021; R&D expenses rose to $18.5M.","Cash and equivalents $174.7M with no debt; FY 2022 cash burn guidance $80-90M.","Over 650 patients now enrolled in simufilam Phase 3 studies, up from 150 six months ago.","Open-label study results expected year-end 2022; Cognition Maintenance Study results Q3 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-007153","json":"https://secwatch.observer/filing/0001171843-22-007153.json","markdown":"https://secwatch.observer/filing/0001171843-22-007153.md","text":"https://secwatch.observer/filing/0001171843-22-007153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000117184322007153/0001171843-22-007153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000117184322007153/f8k_110422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:59:02.259672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ce252c3337e57f0b30a00f80e06fa872ace079cb","claim":"FILANA THERAPEUTICS, INC. updated its full-year 2022 guidance (reaffirmed).","evidence_excerpt":"Net cash use for operations for full-year 2022 is expected to be approximately $80 to $90 million, consistent with previous guidance.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000117184322007153/0001171843-22-007153-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"e049d0775b59212a9a03ce15ef84455d7437ed01","claim":"FILANA THERAPEUTICS, INC. reported the third quarter ended September 30, 2022 results: net income $20.3 million, or $0.51 per share, EPS $0.51 per share.","evidence_excerpt":"Net loss for third quarter 2022 was $20.3 million, or $0.51 per share, compared to a net loss of $9.6 million, or $0.24 per share, for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000117184322007153/0001171843-22-007153-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"$20.3 million, or $0.51 per share"},{"label":"EPS","value":"$0.51 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}